Brava Diagnostics is developing diagnostic products for the acute care market. The Company is seeking seed financing to fund product development for rapid multiplex point-of-care tests for emergency medicine and critical care.
Evanescent planar waveguide technology is the core technology. MBio Diagnostics developed the platform over ten years and has commercialized products outside of human health. Brava will build on these accomplishments by adapting the instrument for the healthcare market, developing in vitro diagnostic assays and executing clinical trials.
Our cardiac marker assays address a worldwide market that is projected to reach $3.5 billion by 2021. Our first tests will be to assess chest pain and shortness of breath in the emergency department. The next assays will address sepsis, the highest cost disease state in U.S. health systems.
High Cost, High Incidence Diseases
Our initial products will address cardiovascular disease and sepsis.
Among the most prevalent of life-threatening diseases are heart attack and heart failure. According to the 2014 National Hospital Ambulatory Medical Care Survey, U.S. emergency departments ordered or ran 7.6 million cardiac enzyme tests to assess chest pain and 3.6 million BNP tests to diagnose heart failure. The worldwide market for cardiac markers was approximately $2.3 billion in 2016 and is projected to reach $3.5 billion by 2021 (8.8% CAGR). Our initial cardiac marker assays will address the unmet need for rapid, accurate tests to manage these high-cost conditions.
Sepsis costs the U.S. health system $24 billion annually and is the most expensive condition to manage. There are approximately 5.3 million patients to screen in the U.S. alone. Brava tests are under development to differentiate bacterial from viral infections and to assess disease status.
Download our Fact Sheet
Download a 2-page strategy summary.
Schedule a meeting